Silicate-substituted calcium phosphate as a bone void filler after kyphoplasty in a young patient with multiple compression fractures due to osteogenesis imperfecta variant

Case report


Department of Orthopaedic Surgery, Uniformed Services University of the Health Sciences, Naval Medical Center, Portsmouth, Virginia

Kyphoplasty can be used to treat compression fractures resulting from a variety of causes. The use of polymethyl methacrylate (PMMA) in conjunction with kyphoplasty has many risks and potential complications, however, particularly in the younger patient population. Silicate-substituted calcium phosphate (Actifuse Synthetic Bone Graft; Apatech, Ltd.) is an alternative to PMMA that provides immediate pain relief and the ability to heal and incorporate within the vertebral body.

KEY WORDS • compression fracture • osteogenesis imperfecta • kyphoplasty • bone graft

KYPHOPLASTY with PMMA is an accepted treatment for osteoporotic compression fractures of the thoracic and lumbar spine that are resistant to conservative treatment.1,2,3,6,9,10,12,19,23 Indications for kyphoplasty have expanded to include compression fractures associated with hemangiomas,1 myeloma,3 and other neoplastic processes.4,6,8 There is concern, however, about the intraoperative, perioperative, and postoperative complications associated with PMMA.5,7,9,12,14,24 As a result, alternative bone-filling materials have been investigated to minimize the potential complications associated with PMMA.5,9 In this case study we present a young patient with multiple compression fractures associated with a rare metabolic disorder that were treated with kyphoplasty in which a silicate-substituted calcium phosphate bone filler (Actifuse Synthetic Bone Graft; Apatech, Ltd.) was used.

Case Report

**History and Examination.** This 25-year-old man presented with a 13-month history of low-back pain radiating to the right lower extremity, accompanied by numbness and paresthesias. He rated his back pain as a 5 on a scale of 0 to 10 in intensity, worsening to an 8 with minimal activities. On physical examination, the patient had tenderness to palpation of the lower lumbar spine and asymmetrical weakness of the right quadriceps. Initial AP and lateral radiographs of the lumbar spine (Fig. 1) showed compression fractures of nearly all VBs, with a radiographic appearance of osteoporosis. Magnetic resonance imaging of the lumbar spine (Fig. 2) revealed multiple compression fractures and foraminal stenosis in the right L3–4 and L4–5. Dual-energy x-ray absorptiometry of the lumbar spine showed a bone mineral density of 0.62 and a T-score of −4.28, which is consistent with severe osteoporosis. After an extensive metabolic evaluation, a rare variant of osteogenesis imperfecta was diagnosed. The patient’s pain failed to improve despite bracing, medication, and activity modification that continued for 9 months. He therefore underwent kyphoplasty of L-3, L-4, and L-5 in which silicate-substituted calcium phosphate was used as a bone void filler, and foraminotomy of the right L3–4 and L4–5 was also performed.

**Operation.** A void was created in each vertebra by using a balloon tamp (Kyphon), and silicate-substituted calcium phosphate crystals were inserted through a 4-mm cannula into the L-3, L-4, and L-5 VBs. The amount of bone filler inserted was determined by the volume of the void created by the balloon tamp. Kyphoplasty at L-3 and L-4 was performed via a unipedicular approach, whereas the L-5 kyphoplasty was performed via a bipedicular approach. The bone void filler was easily visualized using fluoroscopic imaging intraoperatively (Fig. 3). The right L-3 and L-4 nerve roots were decompressed without incident. The

Abbreviations used in this paper: AP = anteroposterior; CT = computed tomography; PMMA = polymethyl methacrylate; VB = vertebral body.
patient tolerated the procedure well without complications.

**Postoperative Course.** On postoperative Day 1, before the patient was discharged, standing AP and lateral radiographs of the lumbar spine were obtained (Fig. 4), which showed the bone void filler within the VBs. At his initial follow-up appointment 4 weeks postoperatively, the patient described improvement of his back pain and mild improvement of his right leg symptoms. Follow-up radiographs of the lumbar spine (Fig. 5) were obtained at 3 and 5 months postoperatively, and these showed bone incorporation. Axial (Fig. 6A and B) and sagittal (Fig. 6C) CT scans of the lumbar spine obtained 9 months postoperatively demonstrated trabecular bone forming into the bone filler and no lucency around the bone filler, confirming bone incorporation of the silicate-substituted calcium phosphate crystals within the VBs. Clinically, the patient had minimal back pain at the most recent follow-up visit 9 months postoperatively.

**Discussion**

There were few good treatment options for this relatively young patient who presented with debilitating back pain due to multiple compression fractures and severe osteoporosis. Posterior lumbar fusion was a poor option for this patient, given his inferior quality of bone and his young age. Kyphoplasty was a viable option for treating the compression fractures, but there is debate about the appropriate bone void filler.

Traditionally, PMMA is used in kyphoplasty to provide immediate structural support from within the VB. The benefits of PMMA are that it hardens quickly after insertion, is relatively inexpensive, and is easy to inject. However, PMMA has many potential drawbacks. There is concern for extravasation of PMMA outside the confines of the VB, with potential injury to nerves and vascular structures.\(^7\)\(^,\)\(^12\) The release of methyl methacrylate monomer into the vascular system during injection can result in acute hypotension, and there have been reports of cardiovascular collapse.\(^14\) Also, PMMA cannot be incorporated biologically into the VB and remains, in essence, a foreign substance within the VB. There is also concern that the difference in modulus of elasticity of PMMA compared with native and osteoporotic bone could result in additional compression fractures at adjacent vertebrae.\(^2\) These potential side effects of PMMA are a concern in all patients, but they are particularly salient in this young one.

Although there is a case report describing the use of PMMA augmentation in treating a single-level compression fracture due to osteogenesis imperfecta,\(^13\) that patient was 57 years old. Our patient, on the other hand, was 25 years old and had multiple levels requiring treatment. We believed that a better choice would be a more biological bone void filler with the potential to form new bone and incorporate into the VB.

There are reports of alternative materials considered for use in patients undergoing kyphoplasty or vertebroplasty, including calcium phosphate and calcium sulfate.\(^13\) Although calcium phosphate can provide structural support and osteoconduction, there are concerns about its ability to produce healing in metabolically diseased bone. Combining bone morphogenetic protein–2 with the calcium phosphate\(^2\) could improve its osteoinductive properties, but this substance is very expensive. Calcium sulfate
can provide an osteoconductive scaffold, but it tends to be rapidly resorbed, limiting its usefulness in vertebral augmentation.

Silicate-substituted calcium phosphate has unique characteristics that make it the most appropriate selection. Silicate-substituted calcium phosphate is a phase-pure 80% porous calcium phosphate material in which the phosphate groups are selectively replaced with silicate ions. Whereas the calcium phosphate scaffolding has the structural support and osteoconduction of traditional calcium phosphate bone filler, the addition of silicate ions increases its osteoinductive properties. Studies have shown that silicon, in vivo, enhances osteoblastic differentiation and stimulates the formation of bone. Moreover, in some reports it has been suggested that silicon is a significant dietary trace element for bone formation and remodeling.

These osteoinductive properties combined with the osteoconductive microstructure of the calcium phosphate lattice provide a rich environment for rapid bone incorporation. This was radiographically evident in our patient on the postoperative x-ray films and CT scan obtained 9 months postoperatively, which showed incorporation of bone within the VB. Additionally, the granules of silicate-substituted calcium phosphate provided structural support of the compressed vertebrae. This was clinically evident in the improvement of the patient’s back pain at the initial postoperative visit at 4 weeks.

The use of silicate-substituted calcium phosphate after kyphoplasty allowed this patient with compression fractures to gain enough structural support to provide early

Fig. 3. Intraoperative fluoroscopic images of L-3, L-4, and L-5 kyphoplasty.

Fig. 4. Standing AP (left) and lateral (right) radiographs of the lumbar spine obtained on postoperative Day 1.

Fig. 5. Follow-up AP radiographs of the lumbar spine obtained 3 (A) and 5 months (B) postoperatively. Follow-up lateral radiographs of the lumbar spine obtained 3 (C) and 5 months (D) postoperatively.
relief of back pain while providing a substrate for incorporation and healing within the bone of the VB. Through this approach, we were able to treat multiple compression fractures successfully in a young adult with severe osteoporosis and avoid using PMMA, with all of its potential short- and long-term complications.

Conclusions
Silicate-substituted calcium phosphate is an ideal substance to use in conjunction with kyphoplasty for the treatment of compression fractures. In this case report we show that Actifuse gives immediate structural support sufficient to decrease pain from compression fractures in the postoperative period and facilitates bone incorporation due to the osteoinductive properties of the silicate ions, even in metabolically diseased bone. Actifuse is radiopaque and easily visualized using fluoroscopic and radiographic imaging.

References
20. Reffitt DM, Ogston N, Jugdaohsingh R, Cheung HF, Evans BA,
Synthetic bone graft as a bone void filler after kyphoplasty


Manuscript received June 30, 2006.
Accepted in final form October 30, 2006.
Address reprint requests to: Mitchell A. Hardenbrook, M.D., L.C.D.R., M.C., U.S.N., Department of Orthopaedic Surgery, Uniformed Services University of the Health Sciences, Naval Medical Center, 620 John Paul Jones Circle, Portsmouth, Virginia 23708–2197. email: mahardenbrook@mar.med.navy.mil.